This is not the most recent version of the article. View current version (16 MAY 2012)

Intervention Protocol

Carnitine for fatigue in multiple sclerosis

  1. Aaron Tejani1,*,
  2. Rae Spiwak2,
  3. Michael Wasdell2,
  4. Greg Rowell3,
  5. Shabita Nathwani4

Editorial Group: Cochrane Multiple Sclerosis Group

Published Online: 16 JUL 2008

Assessed as up-to-date: 15 APR 2008

DOI: 10.1002/14651858.CD007280


How to Cite

Tejani A, Spiwak R, Wasdell M, Rowell G, Nathwani S. Carnitine for fatigue in multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD007280. DOI: 10.1002/14651858.CD007280.

Author Information

  1. 1

    Fraser Health Authority, Clinical Research and Drug Information, Burnaby, BC, Canada

  2. 2

    Fraser Health c/o Burnaby Hospital, Research, Burnaby, BC, Canada

  3. 3

    Fraser Health c/o Burnaby Hospital, Library Service, Burnaby, BC, Canada

  4. 4

    University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, Canada

*Aaron Tejani, Clinical Research and Drug Information, Fraser Health Authority, 3935 Kincaid Street, Burnaby, BC, V5G 2X6, Canada. Aaron.Tejani@fraserhealth.ca.

Publication History

  1. Publication Status: New
  2. Published Online: 16 JUL 2008

SEARCH

This is not the most recent version of the article. View current version (16 MAY 2012)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess whether carnitine (enteral or intravenous) supplementation can improve the quality of life and reduce the symptoms of fatigue in patients with MS-related fatigue. In addition the aim is to identify the adverse effects of carnitine when used in patients with MS fatigue.